A Plus Biotechnology Co

A Plus Biotechnology Co EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of A Plus Biotechnology Co (6918.TWO) as of Oct 27, 2026 is 17.11. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 17.93 — a change of -4.53% (lower).

EV/FCF

17.11

YoY

-4.53%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of A Plus Biotechnology Co is 2024 17.11 . EV/FCF (Enterprise Value to Free Cash Flow) of A Plus Biotechnology Co was 2023 17.93 . It decreases by -4.53% lower compared to the previous year.

The A Plus Biotechnology Co EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
70.48 TWD
Jan 1, 2020
24.70 TWD
Jan 1, 2021
-16.22 TWD
Jan 1, 2022
116.58 TWD
Jan 1, 2023
17.93 TWD
Jan 1, 2024
17.11 TWD
The A Plus Biotechnology Co EV/FCF history
YEAREV/FCFYoY
17.11-4.53%
17.93-84.62%
116.58-818.68%
-16.22-165.68%
24.70-64.96%
70.48—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

A Plus Biotechnology Co Stock analysis

What does A Plus Biotechnology Co do? A Plus Biotechnology Co., Ltd. generates revenue through the research, development, manufacture, and sales of orthopedic medical equipment. The company offers trauma products such as orthopedic internal fixation bone plates, bone nails, and external fixators for stable fracture fixation. Orthopedic products include knee arthritis correction systems and hallux valgus correction systems, while spinal products feature spinal fixation systems and spinal intervertebral fusion devices. Proxy products encompass artificial bone replacement and cartilage repair solutions. The company primarily sells its products domestically in Taiwan and exports to mainland China, Asia, the United States, and Africa, serving healthcare providers and medical institutions across these regions. Trauma products are utilized for stabilizing fractures across various bone types and locations, with applications including intramedullary nails and cables. Orthopedic products assist in precise correction and fixation, such as additive manufacturing surgical guide plates. Spinal products support spinal fixation and intervertebral height maintenance through spinal intervertebral fusion devices. Proxy products like cell therapy and artificial bone replacement cater to tissue repair and regeneration needs. The company's export markets include mainland China, Asia, the United States, and Africa, with domestic sales in Taiwan forming a significant segment. The company's product portfolio includes orthopedic internal fixation bone plates, bone nails, and spinal fixation systems, which are sold to medical institutions and healthcare providers. Trauma products such as external fixators and intramedullary nails are distributed to hospitals and clinics for fracture treatment. Orthopedic products like knee arthritis correction systems are targeted at specialized surgical procedures. Spinal products including intervertebral fusion devices are used in spinal surgeries. Proxy products such as cartilage repair solutions and cell therapy are supplied to medical facilities requiring tissue regeneration treatments. A Plus Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about A Plus Biotechnology Co stock

EV/FCF (Enterprise Value to Free Cash Flow) of A Plus Biotechnology Co is 17.11 in 2024.

EV/FCF (Enterprise Value to Free Cash Flow) of A Plus Biotechnology Co changed from 17.93 to 17.11, representing a -4.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) A Plus Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s A Plus Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — A Plus Biotechnology Co

All Key Metrics — A Plus Biotechnology Co